ISIN | LU1334634299 |
---|---|
Valorennummer | 30671916 |
Bloomberg Global ID | |
Fondsname | Crossfund Sicav - Crossinvest Healthcare Fund A USD |
Fondsanbieter |
Crossinvest SA
Lugano, Schweiz Telefon: +41 91 911 88 88 E-Mail: info@crossinvest.ch Web: www.crossinvest.ch |
Fondsanbieter | Crossinvest SA |
Vertreter in der Schweiz |
FundPartner Solutions (Suisse) SA Genève 75 |
Distributor(en) |
FundPartner Solutions (Suisse) SA Genève 3 |
Anlagekategorie | Aktienfonds |
EFC-Kategorie | |
Anteilskategorie | Accumulation |
Domizilland | Luxemburg |
Konditionen bei der Ausgabe | Kombination von Ausgabekommission zugunsten der Fondsleitung und Transaktionsgebühr zugunsten des Fonds |
Konditionen bei der Rücknahme | Kombination von Rücknahmekommission zugunsten der Fondsleitung und Transaktionsgebühr zugunsten des Fonds |
Investment-Strategie *** | The investment objective of the Sub‐Fund is to achieve a long term capital appreciation by pursuing sector focus exposure opportunities in companies involved in health and personal care. These companies could participate in the research, clinical development or commercialization of medicines, equipment or services for disease treatment or life style improvement. The investment focus will be on industry leaders that offer premium growth and/or profitability prospects, pipeline and valuation upside. The Sub‐Fund is actively managed. The Sub‐Fund has no benchmark index and is not managed in reference to a benchmark index. |
Besonderheiten |
Aktueller Preis * | 165.34 USD | 30.10.2024 |
---|---|---|
Vorheriger Preis * | 166.69 USD | 29.10.2024 |
52 Wochen Hoch * | 178.62 USD | 30.08.2024 |
52 Wochen Tief * | 141.10 USD | 10.11.2023 |
NAV * | 165.34 USD | 30.10.2024 |
Ausgabepreis * | 165.34 USD | 30.10.2024 |
Rücknahmepreis * | ||
Schlusskurs * | ||
Indikativer Minimalpreis | ||
Fondsvermögen *** | 76'656'825 | |
Anteilsklassevermögen *** | 11'371'809 | |
Trading Information SIX |
YTD-Performance | +6.51% |
29.12.2023 - 30.10.2024
29.12.2023 30.10.2024 |
---|---|---|
YTD-Performance (in CHF) | +9.64% |
29.12.2023 - 30.10.2024
29.12.2023 30.10.2024 |
1 Monat | -4.02% |
30.09.2024 - 30.10.2024
30.09.2024 30.10.2024 |
3 Monate | -3.05% |
30.07.2024 - 30.10.2024
30.07.2024 30.10.2024 |
6 Monate | +2.99% |
30.04.2024 - 30.10.2024
30.04.2024 30.10.2024 |
1 Jahr | +18.85% |
30.10.2023 - 30.10.2024
30.10.2023 30.10.2024 |
2 Jahre | +8.96% |
31.10.2022 - 30.10.2024
31.10.2022 30.10.2024 |
3 Jahre | -2.38% |
02.11.2021 - 30.10.2024
02.11.2021 30.10.2024 |
5 Jahre | +30.94% |
30.10.2019 - 30.10.2024
30.10.2019 30.10.2024 |
Kapitalbeteiligungsquote in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Anteil am Gesamtvermögen in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Immobilienquote in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Eli Lilly and Co | 9.38% | |
---|---|---|
Novo Nordisk AS Class B | 5.96% | |
Merck & Co Inc | 4.37% | |
AbbVie Inc | 4.36% | |
Johnson & Johnson | 4.30% | |
UnitedHealth Group Inc | 4.20% | |
AstraZeneca PLC | 3.98% | |
Novartis AG Registered Shares | 3.40% | |
Stryker Corp | 3.20% | |
Edwards Lifesciences Corp | 2.94% | |
Letzte Daten-Aktualisierung | 30.06.2024 |
TER | |
---|---|
Datum TER | |
Performance Fee *** | 15.00% |
PTR | |
Max. Management Fee *** | 1.50% |
Ongoing Charges *** | 1.98% |
SRRI ***
|
|
Datum SRRI *** | 30.09.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |